Table 4

EULAR response, low disease activity and remission rates during TNF inhibitor treatment of the rheumatoid arthritis cohort
3 months 6 months 12 months
Good response (%) 39.5 45.8 50.5
Moderate response (%) 49.5 39.8 31.9
Nonresponse (%) 14 14.4 17.6
DAS28(4v)-CRP <3.2 (%) 42.3 50.9 54.9
Low disease activity (%) 18.5 20.5 17.6
DAS28 remission 53 (23.9%) 65 (30.1%) 102 (37.4%)
Boolean remission 7 (3.2%) 23 (10.6%) 27 (9.9%)

EULAR, European League Against Rheumatism, TNF, tumour necrosis factor; DAS28(4v)-CRP, disease activity score based on joints using four variables and including C-reactive protein as the inflammatory marker; DAS28, disease activity score based on 28 joints.

Balogh et al.

Balogh et al. Arthritis Research & Therapy 2013 15:R221   doi:10.1186/ar4421

Open Data